Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selexipag continuation versus discontinuation after balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension
jRCTs051250128Recruiting
- Sponsor
- Nippon Shinyaku
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of selexipag in chronic thromboembolic pulmonary hypertension (CTEPH) (2 arms), sponsored by Nippon Shinyaku. Primary endpoint: Percent change from baseline in pulmonary vascular resistance. Started Jul 2026; status: recruiting.
02
Drugs
selexipag
03
Conditions
chronic thromboembolic pulmonary hypertension (CTEPH)
Beyond the preview
Go deeper on jRCTs051250128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051250128.